Blar i Institutt for nevromedisin og bevegelsesvitenskap på forfatter "Pawel, Mielnik"
-
Discontinuation rate of sulfasalazine, leflunomide and methotrexate due to adverse events in a real-life setting (NOR-DMARD)
Pawel, Mielnik; Sexton, Joseph; Fagerli, Karen Minde; Bakland, Gunnstein; Hu, Yi; Kristianslund, Eirik; Hoff, Mari; Wierød, Ada; Kvien, Tore Kristian Aaserud (Peer reviewed; Journal article, 2023)Objectives MTX, LEF and SSZ are conventional synthetic DMARDs (csDMARDs) with a well-established role in the treatment of RA. We aimed to estimate and compare the relative risks for adverse events (AEs) and the ... -
Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010–2019 – a country with a national tender system for prescription of costly drugs
Brkic, Alen; Diamantopoulos, Andreas P; Haavardsholm, Espen A.; Fevang, Bjørg Tilde Svanes; Brekke, Lene Kristin; Loli, Liz Paucar; Zettel, Camilla; Rødevand, Erik; Bakland, Gunnstein; Pawel, Mielnik; Haugeberg, Glenn (Peer reviewed; Journal article, 2022)Background In Norway, an annual tender system for the prescription of biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) has been used since 2007. This study aimed to explore annual ... -
Exploring the impact of the national tender system on the use of costly drugs treating rheumatoid arthritis patients in ten rheumatology centers in Norway (2010–2019)
Brkic, Alen; Diamantopoulos, Andreas P; Hoff, Mari; Haavardsholm, Espen A.; Fevang, Bjørg Tilde Svanes; Brekke, Lene Kristin; Loli, Liz Paucar; Zettel, Camilla; Bakland, Gunnstein; Pawel, Mielnik; Haugeberg, Glenn (Peer reviewed; Journal article, 2023)Background Biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) are highly effective in treating rheumatoid arthritis (RA), albeit high drug cost has restricted their use in many countries. ...